NEW YORK (GenomeWeb) – Synthetic biology startup Pareto Biotechnologies announced today a technology partnership with DNA2.0 to integrate their technologies to hasten the engineering of proteins in Pareto's pipeline.
Pareto, based in San Francisco, said it will merge its synthetic biology pipeline platform with DNA2.0's ProteinGPS engineering technology to identify and quantify protein genetic mutations for incorporation into iterative rounds of improved synthetic genes. Pareto will also leverage DNA2.0's technologies to "increase the efficacy of its own platform to generate flavors, fragrances, and cosmetics with improved and novel properties," it added in a statement.
Financial and other terms of the deal were not disclosed.
"Our deep understanding of the structures of these classes of enzymes, along with a statistical optimization algorithm from DNA2.0 gets us the best of both worlds: rational design and robust enzyme improvement," Pareto CEO Jamie Bacher said. "Through our relationship with DNA2.0, we'll be able to generate completely novel molecules with applicability to flavors and fragrances, cosmetics, and therapeutics."